Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.65 +2.5%	$1.88	$1.21 ▼ $3.81	$40.75M	0.68	261,100 shs	467,902 shs
EGRX Eagle Pharmaceuticals	$3.19 +0.3%	$3.14	$1.50 ▼ $3.87	$41.43M	0.83	6,795 shs	341 shs
IMCC IM Cannabis	$2.27 -10.3%	$2.83	$1.29 ▼ $7.12	$11.91M	2.2	116,420 shs	69,738 shs
NRXP NRx Pharmaceuticals	$2.62 +4.4%	$3.03	$1.10 ▼ $6.01	$45.30M	1.59	503,532 shs	263,117 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+0.63%	-4.73%	-10.56%	-19.10%	+3.21%
EGRX Eagle Pharmaceuticals	-18.75%	-18.75%	-29.73%	+57.58%	-43.48%
IMCC IM Cannabis	-1.94%	-2.69%	-26.02%	+48.04%	-16.23%
NRXP NRx Pharmaceuticals	-9.06%	+5.02%	-14.63%	-4.56%	+44.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.5469 of 5 stars	1.0	0.0	0.0	0.6	2.5	1.3
EGRX Eagle Pharmaceuticals	1.7958 of 5 stars	0.0	2.0	3.9	0.0	3.3	0.0
IMCC IM Cannabis	0.9189 of 5 stars	0.0	5.0	0.0	3.1	0.0	0.0
NRXP NRx Pharmaceuticals	3.0883 of 5 stars	3.6	5.0	0.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	1.01% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
IMCC IM Cannabis	0.00	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	987.79% Upside

Current Analyst Ratings Breakdown

Latest IMCC, AADI, EGRX, and NRXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/11/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
8/4/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/20/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
6/6/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.63	N/A	N/A	$4.29 per share	0.38
EGRX Eagle Pharmaceuticals	$257.55M	0.16	$7.98 per share	0.40	N/A	∞
IMCC IM Cannabis	$52.41M	0.23	N/A	N/A	$0.56 per share	4.05
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.48) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	11/4/2025 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	-$7.72M	-$0.54	N/A	N/A	N/A	-4.19%	-59.80%	-5.15%	N/A
NRXP NRx Pharmaceuticals	-$25.13M	-$2.24	N/A	N/A	N/A	N/A	N/A	-540.51%	N/A

Latest IMCC, AADI, EGRX, and NRXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/18/2025	Q2 2025	NRXP NRx Pharmaceuticals	-$0.31	-$0.98	-$0.67	-$0.98	N/A	N/A
8/12/2025	Q2 2025	IMCC IM Cannabis	-$0.1367	-$0.0653	+$0.0714	-$0.07	$12.88 million	$9.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMCC IM Cannabis	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
IMCC IM Cannabis	0.32	0.72	0.62
NRXP NRx Pharmaceuticals	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
EGRX Eagle Pharmaceuticals	85.36%
IMCC IM Cannabis	7.68%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
EGRX Eagle Pharmaceuticals	28.90%
IMCC IM Cannabis	5.91%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
IMCC IM Cannabis	340	5.25 million	N/A	Not Optionable
NRXP NRx Pharmaceuticals	2	17.29 million	14.00 million	Optionable

IMCC, AADI, EGRX, and NRXP Headlines

Recent News About These Companies

NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript

4 hours ago | seekingalpha.com

NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital

August 20 at 2:17 AM | americanbankingnews.com

Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc ...

August 19 at 9:47 PM | theglobeandmail.com

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs

August 19 at 4:46 PM | msn.com

Nrx Pharmaceuticals Faces Financing Hurdles in Strategic Acquisitions of Kadima and Dura Medical

August 19 at 11:45 AM | msn.com

NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Report Preview: What to Expect

August 19 at 11:45 AM | finance.yahoo.com

NRx Pharmaceuticals sees cash runway into 2026

August 18 at 1:32 PM | msn.com

What To Expect From NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings

August 18 at 1:32 PM | finance.yahoo.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and ...

August 18 at 9:29 AM | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and ...

August 18 at 8:40 AM | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 18 at 8:10 AM | globenewswire.com

NRX Pharmaceuticals Gains FDA Fast Track for NRX-100

August 16, 2025 | msn.com

Insights Ahead: NRX Pharmaceuticals's Quarterly Earnings

August 14, 2025 | benzinga.com

NRx Pharmaceuticals' (NRXP) "Buy" Rating Reiterated at D. Boral Capital

August 14, 2025 | americanbankingnews.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results ...

August 13, 2025 | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

August 13, 2025 | prnewswire.com

NRx Pharmaceuticals to Report Q2 2025 Results on August 14

August 13, 2025 | msn.com

New to The Street Client NRx Pharmaceuticals (NASDAQ:NRXP) Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation

August 12, 2025 | miamiherald.comM

NRx Pharmaceuticals (NRXP) Projected to Post Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

New to The Street Client NRx Pharmaceuticals Secures FDA Fast Track Designation for NRX-100, Expanding Reach to 13 Million Americans Confronting Suicidal Ideation

August 11, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCC, AADI, EGRX, and NRXP Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.65 +0.04 (+2.48%)

As of 08/19/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.19 +0.01 (+0.31%)

As of 12:12 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

IM Cannabis NASDAQ:IMCC

$2.27 -0.26 (-10.28%)

Closing price 04:00 PM Eastern

Extended Trading

$2.27 0.00 (0.00%)

As of 04:10 PM Eastern

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

NRx Pharmaceuticals NASDAQ:NRXP

$2.62 +0.11 (+4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.60 -0.02 (-0.57%)

As of 04:10 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time